Biotech, pharmaceutical and medtech news: clinical trials, approvals, deals and healthcare markets.
Iron Horse Acquisitions Corp., a special purpose acquisition company (SPAC) listed on NASDAQ under the ticker IROH, has announced a definitive business combination agreement with Rosey Sea Holdings Limited, the parent company of Zhong Guo Liang Tou Group Limited, which operates under the name China Food Investment (CFI). The agreement,
Silexion Therapeutics (NASDAQ: SLXN) has reported promising preclinical data for SIL-204, its next-generation siRNA candidate targeting KRAS mutations in pancreatic cancer. This announcement comes just days after the company revealed strong results from its Phase 2 trial of LODER™, another RNAi-based therapy designed for pancreatic cancer treatment.
Silexion Therapeutics (NASDAQ: SLXN), a biotech company focused on innovative RNA interference (RNAi) therapies, has announced promising new data from its Phase 2 trial of LODER™, targeting patients with non-resectable locally advanced pancreatic cancer (LAPC). The data highlights a 56% objective response rate (ORR) and a 67% increase in
On Saturday morning, a collision involving two vehicles in Holmdel, New Jersey resulted in a car crashing into a local food business, causing injuries and temporary closure of the establishment. The incident occurred near Holmdel Road at approximately 10:30 AM, according to information shared by the Holmdel Police Department
The rapid ascent of Summit Therapeutics (NASDAQ: SMMT), driven by the success of its targeted NSCLC therapy ivonescimab, has shined a spotlight on the growing potential of precision oncology. While Summit captured attention with its dramatic Phase 3 results, other companies are emerging with equally promising, innovative approaches to cancer
Curatis Holding has reported its financial results for the first half of 2024, showcasing significant growth in its core distribution business despite only including two months of data from its recently acquired subsidiary, Curatis AG. The company’s revenues reached CHF 2.0 million, with Curatis AG contributing to this
